EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses

David M Morens, Jeffery K Taubenberger, Anthony S Fauci

Cell Host & Microbe · 2023-01 · 31 (1) · 146-157

DOI: 10.1016/j.chom.2022.11.016 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cell Host & Microbe, 2023-01. Verfasst von David M Morens und 2 weiteren Autor:innen. Beteiligte Einrichtung: Office of the Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Hauptthemen laut MEDLINE: COVID-19, Orthomyxoviridae, Influenza, Human, Influenza Vaccines. Die Arbeit wurde bisher 202-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute of Allergy and Infectious Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Viruses that replicate in the human respiratory mucosa without infecting systemically, including influenza A, SARS-CoV-2, endemic coronaviruses, RSV, and many other "common cold" viruses, cause significant mortality and morbidity and are important public health concerns. Because these viruses generally do not elicit complete and durable protective immunity by themselves, they have not to date been effectively controlled by licensed or experimental vaccines. In this review, we examine challenges that have impeded development of effective mucosal respiratory vaccines, emphasizing that all of these viruses replicate extremely rapidly in the surface epithelium and are quickly transmitted to other hosts, within a narrow window of time before adaptive immune responses are fully marshaled. We discuss possible approaches to developing next-generation vaccines against these viruses, in consideration of several variables such as vaccine antigen configuration, dose and adjuventation, route and timing of vaccination, vaccine boosting, adjunctive therapies, and options for public health vaccination polices.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19OrthomyxoviridaeInfluenza, HumanInfluenza VaccinesHumansSARS-CoV-2Antibodies, Viral

Substanzen

Influenza VaccinesAntibodies, Viral

Autor:innen und Institutionen

  • Office of the Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: taubenberge…

Förderung

  • National Institute of Allergy and Infectious Diseases
  • Division of Intramural Research, National Institute of Allergy and Infectious Diseases
  • National Institutes of Health

Zitieren

APA

Morens, D. M., Taubenberger, J. K., & Fauci, A. S. (2023). Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses. Cell Host & Microbe, 31(1), 146-157. https://doi.org/10.1016/j.chom.2022.11.016

Vancouver

Morens DM, Taubenberger JK, Fauci AS. Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses. Cell Host & Microbe. 2023;31(1):146-157. doi:10.1016/j.chom.2022.11.016

BibTeX
@article{Morens2023,
  author = {Morens, David M and Taubenberger, Jeffery K and Fauci, Anthony S},
  title = {Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses},
  journal = {Cell Host & Microbe},
  year = {2023},
  volume = {31},
  number = {1},
  pages = {146--157},
  doi = {10.1016/j.chom.2022.11.016}
}
Kostenlos starten →